A clinical trial is underway at the University of Alabama at Birmingham (UAB) to examine the effects of sacubitril/valsartan on glucose metabolism in healthy African American adults. The study seeks to understand how this medication, commonly used for blood pressure management, influences the way the body processes sugar in individuals without pre-existing conditions like diabetes.
Study Design and Eligibility
The trial is enrolling healthy African American men and women between the ages of 18 and 60. Participants must have no history of diabetes, heart disease, or kidney problems to ensure a focus on the medication's effects on baseline glucose metabolism. The study protocol involves participants performing exercise, taking sacubitril/valsartan, and providing blood samples for analysis.
Sacubitril/Valsartan and Glucose Metabolism
Sacubitril/valsartan is a combination medication primarily used to treat heart failure and hypertension. The trial aims to explore its potential impact on glucose metabolism, an area of increasing research interest. Understanding how sacubitril/valsartan affects glucose handling in healthy individuals could provide insights into its broader metabolic effects and potential applications.
Participant Compensation
Participants who complete all study visits will receive $675 as compensation for their time and effort. This compensation aims to encourage participation and ensure adequate representation in the study.
Contact Information
Individuals interested in participating in the study are encouraged to contact Tiffany at 205-934-0534 or via email at nauticalstudy@uabmc.edu.
